While all states cover at least one Type 2 diabetes-indicated GLP-1, coverage for obesity-indicated options is less consistent
Some patients focus only on the medication price without considering the complete cost of physician-guided care
For many non-pregnant adults with diabetes, a common treatment target is an HbA1c below 7%, although targets may vary depending on age, comorbidities, and risk of hypoglycemia
What is the primary driver in this market
This consistency is particularly important if biomarker assessment or genetic testing informs your personalized dosing strategy, as degraded medication can obscure true individual response patterns
If you are looking specifically for semaglutide dosing at weight loss levels (1.7 mg or 2.4 mg), you may need to call ahead to confirm availability